# A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer

> **NCT02999295** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Center, Japan** · enrollment: 46 (actual)

## Conditions studied

- Gastric Cancer
- Gastroesophageal Junction Region (GEJ) Cancer

## Interventions

- **BIOLOGICAL:** Ramucirumab
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT02999295
- **Lead sponsor:** National Cancer Center, Japan
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2017-11
- **Final completion:** 2019-08
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2019-08-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02999295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02999295, "A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02999295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*